Merck and Eisai team up in oncology; Is biotech in a bubble?;

@FierceBiotech: EuroBiotech: Billionaires plot Stallergenes merger, Cerenis set for IPO, Big Pharma-backed Opsona eyes IPO. Report | Follow @FierceBiotech

@JohnCFierce: You know Richard Gonzalez is sweating it out when he gives an interview like this ($ABBV). More from Reuters | Follow @JohnCFierce

@DamianFierce: "In 2009, $PCYC's shares fell to a record low 57 cents. $ABBV is paying cash and stock worth $261.25 a share." WSJ story | Follow @DamianFierce

> Merck ($MRK) and Eisai are teaming up on cancer R&D, planning studies that combine the former's PD-1 inhibitor Keytruda with two of the latter's oncology drugs. More

> Is biotech booming or just in a bubble? Bloomberg takes the temperature of investors and executives in the industry. Story

> Isis Pharmaceuticals ($ISIS) pocketed a $9 million milestone payment as part of its ongoing collaboration with Biogen Idec ($BIIB) in spinal muscular atrophy. News

Medical Device News

@FierceMedDev: Navidea joins forces with Norgine to market cancer imaging Dx in EU. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Now with ""s from OptiNose: Evidence that inhaled oxytocin improves social behavior among autistic patients spurs R&D. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: New superbug outbreak tied to endoscope devices surfaces amid FDA scrutiny. Article | Follow @EmilyWFierce

> EndoChoice raises $57M led by Deerfield to offer a better endoscopy view. News

> J&J ordered to hand over $5.6M in vaginal mesh trial. More

Pharma News

@FiercePharma: Health Canada pledges more plant inspections and more transparency. More from FiercePharmaManufacturing | Follow @FiercePharma

@EricPFierce: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Novartis gets bragging rights on first U.S. biosim. But will its Neupogen copy sell? Story | Follow @CarlyHFierce

> Looking at an IPO? Watch shares soar at Novo Nordisk's newly public IT unit. News

> BMS, Pfizer's Eliquis gets a NICE boost in rivalry with Pradaxa, Xarelto. Article

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.